Attached files
| file | filename |
|---|---|
| 10-Q - CIDARA THERAPEUTICS, INC. FORM 10-Q - Cidara Therapeutics, Inc. | cdtx10-q2017x03.htm |
| EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002 - Cidara Therapeutics, Inc. | exhibit321-q12017.htm |
| EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc. | exhibit312-q12017.htm |
| EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc. | exhibit311-q12017.htm |
| EX-10.2 - FORM OF RESTRICTED STOCK UNIT AWARD GRANT NOTICE - Cidara Therapeutics, Inc. | cidara-restrictedstockunit.htm |
| EX-10.1 - CARB-X COST REIMBURSMENT RESEARCH SUBAWARD AGREEMENT - Cidara Therapeutics, Inc. | carbxagreement.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Cidara Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew Onaitis, Chief Financial Officer and General Counsel of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 10, 2017 | /s/ Matthew Onaitis | |
Matthew Onaitis | ||
Chief Financial Officer and General Counsel | ||
(Principal Financial Officer) | ||
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.